阿尔茨海默病神经影像学倡议
危险系数
神经病理学
痴呆
神经影像学
比例危险模型
萎缩
阿尔茨海默病
样本量测定
临床痴呆评级
疾病
内科学
医学
心理学
肿瘤科
神经科学
置信区间
统计
数学
作者
Emilie T. Reas,Alexey Shadrin,Oleksandr Frei,Ehsan Motazedi,Linda K. McEvoy,Shahram Bahrami,Dennis van der Meer,Carolina Makowski,Robert Loughnan,Xin Wang,Iris Broce,Sarah J. Banks,Vera Fominykh,Weiqiu Cheng,Dominic Holland,Olav B. Smeland,Tyler M. Seibert,Geir Selbæk,James Brewer,Chun Fan,Ole A. Andreassen,Anders M. Dale
摘要
Abstract Introduction There is a pressing need for non‐invasive, cost‐effective tools for early detection of Alzheimer's disease (AD). Methods Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Cox proportional models were conducted to develop a multimodal hazard score (MHS) combining age, a polygenic hazard score (PHS), brain atrophy, and memory to predict conversion from mild cognitive impairment (MCI) to dementia. Power calculations estimated required clinical trial sample sizes after hypothetical enrichment using the MHS. Cox regression determined predicted age of onset for AD pathology from the PHS. Results The MHS predicted conversion from MCI to dementia (hazard ratio for 80th versus 20th percentile: 27.03). Models suggest that application of the MHS could reduce clinical trial sample sizes by 67%. The PHS alone predicted age of onset of amyloid and tau. Discussion The MHS may improve early detection of AD for use in memory clinics or for clinical trial enrichment. HIGHLIGHTS A multimodal hazard score (MHS) combined age, genetics, brain atrophy, and memory. The MHS predicted time to conversion from mild cognitive impairment to dementia. MHS reduced hypothetical Alzheimer's disease (AD) clinical trial sample sizes by 67%. A polygenic hazard score predicted age of onset of AD neuropathology.
科研通智能强力驱动
Strongly Powered by AbleSci AI